EngiCard: a bioengineered heart is no fantasy anymore
According to WHO database there are over 20 % of the population above 75 y.o. suffering because of heart valves diseases (Lancet, March 2024). Furthermore there are more 20 thousands born children with congenital heart valves diseases only in Russia and unfortunately there is no ideal solution to fix it nowadays. The questions are reasonable. Implemented solutions: mechanical prothesis – lifelong usage of anticoagulants (warfarin), violation of natural anatomic structure • biological prothesis – biodegeneration, risk of immunological rejection, calcification • Ross’ operation – massive operational stress, infectious complications, long lasting ischemia, reoperation is necessary sometimes • Ozaki’s procedure – patented and expensive We suggest solution of all drawbacks listed. The solution- 3D-printed model of heart valve based on individual parameters and synthetized with a new polymer material composed of polycaprolactone and diaminocarbonic acids. The frame printed is served as matrix which will be colonized with patient’s cells. Survival rate of seeded cells is over 90 %. An implanted bioprothesis gradually degrade in patient organism while is being germinated with new vessels, tissues and cells. It takes about 3 years.
Biotechnology And National Health
Technologies for human health
5 years approximately
The Russian Federation, B.R.I.C.S. and other friendly countries.
Personalized creation of a new valve growing de novo in vivo • absence of immunological rejection • polymer frame biodegradation preserving normal valve anatomy • growth of the new valve together with heart
-
Publishing of experiments results in process
